Trilaciclib hydrochloride

• CAT Number: I013078
• CAS Number: 1977495-97-8
• Molecular Formula: C₂₄H₃₂Cl₂N₈O
• Molecular Weight: 519.47
• Purity: ≥95%
• Target: CDK
• Solubility: DMSO
• IUPAC Name: 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyrazino[5,6]pyrrolo[1,2-d]pyrimidine-9,1//'-cyclohexane]-6-one;dihydrochloride
• InChI: InChI=1S/C24H30N8O.2ClH/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23;;/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29);2*1H
• InChIKey: BRCYOXKEDFAUSA-UHFFFAOYSA-N
• SMILES: CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6.Cl.Cl

Trilaciclib hydrochloride (Cat.No:I013078) is an investigational drug in the class of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. It is being studied for its potential to preserve bone marrow and hematopoietic stem cells during chemotherapy, reducing myelosuppression. Trilaciclib hydrochloride has shown promise in clinical trials as a supportive therapy for cancer patients undergoing chemotherapy.

Reference

[1]. Bisi JE, et al. Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Mol Cancer Ther. 2016 May;15(5):783-93.